Multiple myeloma clinical trials
642 studies are looking for volunteers right now. Search near you to see which are close by and who can take part.
Or see all multiple myeloma studies in TrialFinder. Live data from ClinicalTrials.gov, updated daily.
At a glance
Where the studies are
U.S. states with the most recruiting multiple myeloma studies. A study counts once in each state where it has a site.
- New York99
- California92
- Florida77
- Texas74
- Georgia69
- North Carolina69
- Massachusetts64
- Ohio58
- New Jersey53
- Minnesota50
- Colorado46
- Michigan45
Also in China (178), France (73), Spain (61), Italy (57), United Kingdom (50), Australia (49), Canada (49), Germany (47).
Types of study
Phases 1 to 4 test medicines, from first safety checks to long-term follow-up after approval. Trials of devices and programs have no phase. Observational studies give no study treatment.
- Early phase 134
- Phase 190
- Phase 1 / Phase 274
- Phase 2140
- Phase 2 / Phase 313
- Phase 352
- Phase 410
- No phase (devices, programs)86
- Observational143
Recently updated studies
Recruiting multiple myeloma studies whose listing changed most recently. Open one in TrialFinder to check if you might qualify.
- RecruitingPhase 3NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Ages 18 Years and over · Daphne, Alabama · Fairhope, Alabama +157 more · Pfizer
- RecruitingPhase 2NCT07891923
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
Ages 18 Years and over · Navi Mumbai, Maharashtra · Tata Memorial Centre
- RecruitingPhase 2NCT07106710
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Ages 18 Years – 70 Years · Tianjin, Tianjin Municipality · Institute of Hematology & Blood Diseases Hospital, China
- RecruitingPhase 1NCT06904066
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Ages 18 Years – 120 Years · Bethesda, Maryland · National Cancer Institute (NCI)
- RecruitingObservationalNCT00900198
Collection of Tissue Samples for Cancer Research
Ages 2 Months and over · Sacramento, California · Aurora, Colorado +15 more · National Cancer Institute (NCI)
- RecruitingPhase 4NCT07609940
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Ages 18 Years and over · Los Angeles, California · St. Petersburg, Florida +5 more · Regeneron Pharmaceuticals
- RecruitingPhase 1NCT06465316
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Ages 18 Years and over · Phoenix, Arizona · Derby, Connecticut +14 more · National Cancer Institute (NCI)
- RecruitingPhase 2NCT07106736
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Ages 18 Years – 75 Years · Tianjin, Tianjin Municipality · Institute of Hematology & Blood Diseases Hospital, China
Worth knowing
- Taking part is your choice, and you can stop at any time.
- Each study has rules about who can join. The study team checks them with you before you start.
- Talk to your doctor about whether a study is a good fit for you.